<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Five patients with primary colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> or anal <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> were started on a 2-weeks-on, 1-week-off <z:chebi fb="0" ids="31348">capecitabine</z:chebi> dosing regimen in addition to other chemotherapeutic agents and/or radiation </plain></SENT>
<SENT sid="1" pm="."><plain>Within the first few doses, patients experienced <z:hpo ids='HP_0100749'>chest pain</z:hpo> and/or <z:hpo ids='HP_0002094'>dyspnea</z:hpo> at rest or with exertion </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> electrocardiographic findings suggestive of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> were found in some cases at initial presentation, and 1 patient had troponin elevation consistent with an <z:hpo ids='HP_0011009'>acute</z:hpo> ST-segment elevation <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Subsequent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> evaluations were not suggestive of clinically significant <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients experienced immediate and sustained relief from <z:hpo ids='HP_0100749'>chest pain</z:hpo> after discontinuation of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> and were able to successfully tolerate retreatment using a novel management strategy based on secondary prophylaxis with diltiazem </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, guidelines for the evaluation of and therapy for <z:chebi fb="0" ids="31348">capecitabine</z:chebi>-induced <z:hpo ids='HP_0100749'>chest pain</z:hpo> are proposed </plain></SENT>
</text></document>